Table II.
Comparison of clinicopathological and immunohistochemical data between 15 cases of ATC and 13 cases of PDTC in 26 patientsa.
| Characteristics | ATC | PDTC | P-value |
|---|---|---|---|
| Age, years | 0.018 | ||
| Median | 67 | 73 | |
| Mean ± SD (range) | 64.53±11.29 (47–83) | 73.55±6.63 (55–87) | |
| Sex, n/total (%) | 0.395 | ||
| Male | 6/15 (40.0) | 2/11 (18.2) | |
| Female | 9/15 (60.0) | 9/11 (81.8) | |
| PD-L1 | |||
| TPS | 9/15 (60.0) | 1/13 (7.7) | 0.006 |
| TILs | 11/15 (73.3) | 0/13 (0.0) | <0.001 |
| CD3 | 15/15 (100.0) | 9/13 (69.2) | 0.035 |
| CD4 | 9/15 (60.0) | 0/13 (0.0) | 0.001 |
| CD8 | 15/15 (100.0) | 7/13 (53.8) | 0.005 |
| CD20 | 7/15 (46.7) | 0/13 (0.0) | 0.007 |
| CD68 | 15/15 (100.0) | 8/13 (61.5) | 0.013 |
| CD163 | 15/15 (100.0) | 9/13 (69.2) | 0.035 |
| S100 | 15/15 (100.0) | 6/13 (46.2) | 0.001 |
| p53 | 11/15 (73.3) | 1/13 (7.7) | 0.001 |
a
Among the 26 patients, coexistence of ATC and PDTC areas was observed in the tumors of 2 patients. ATC, anaplastic thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma; TPS, tumor proportion score; TILs, tumor-infiltrating lymphocytes; PD-L1, programmed death ligand 1.